DK3146062T3 - Anvendelse af ginsenosid m1 til inhibering af nyrefibrose - Google Patents

Anvendelse af ginsenosid m1 til inhibering af nyrefibrose Download PDF

Info

Publication number
DK3146062T3
DK3146062T3 DK15793585.9T DK15793585T DK3146062T3 DK 3146062 T3 DK3146062 T3 DK 3146062T3 DK 15793585 T DK15793585 T DK 15793585T DK 3146062 T3 DK3146062 T3 DK 3146062T3
Authority
DK
Denmark
Prior art keywords
ginsenoside
inhibition
renal fibrosis
fibrosis
renal
Prior art date
Application number
DK15793585.9T
Other languages
English (en)
Inventor
Sheau-Long Lee
Yu-Chieh Lee
Ann Chen
Kuo-Feng Hua
Shuk-Man Ka
Wan-Han Hsu
Original Assignee
Wellhead Biological Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellhead Biological Tech Corp filed Critical Wellhead Biological Tech Corp
Application granted granted Critical
Publication of DK3146062T3 publication Critical patent/DK3146062T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15793585.9T 2014-05-16 2015-05-18 Anvendelse af ginsenosid m1 til inhibering af nyrefibrose DK3146062T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461994486P 2014-05-16 2014-05-16
PCT/CN2015/079156 WO2015172746A1 (en) 2014-05-16 2015-05-18 Use of ginsenoside m1 for inhibiting renal fibrosis

Publications (1)

Publication Number Publication Date
DK3146062T3 true DK3146062T3 (da) 2019-08-12

Family

ID=54479353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15793585.9T DK3146062T3 (da) 2014-05-16 2015-05-18 Anvendelse af ginsenosid m1 til inhibering af nyrefibrose

Country Status (9)

Country Link
US (1) US10357507B2 (da)
EP (1) EP3146062B1 (da)
JP (1) JP6626094B2 (da)
KR (1) KR102360315B1 (da)
CN (1) CN106795546A (da)
DK (1) DK3146062T3 (da)
ES (1) ES2739203T3 (da)
TW (1) TWI670063B (da)
WO (1) WO2015172746A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100381441B1 (ko) * 2000-06-14 2003-04-26 기장 메디칼 주식회사 약쑥과 약재혼합쑥을 이용한 경피흡수제와 그 제조방법 및사용방법
US10172876B2 (en) * 2014-11-03 2019-01-08 Sheau-Long Lee Use of ginsenoside M1 for treating IgA nephropathy
US20210100823A1 (en) * 2018-04-23 2021-04-08 Sheau-Long Lee Use of ginsenoside m1 for treating huntington's disease
CN115297867A (zh) * 2020-02-20 2022-11-04 理筱龙 人参皂甙m1作为血管收缩素调节酶的调节剂及其在治疗包括冠状病毒引起的症状的疾病或病征的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050102326A1 (en) * 2003-10-22 2005-05-12 Nitzan Peleg Method and apparatus for performing conflict resolution in database logging
CN100402038C (zh) * 2004-03-09 2008-07-16 山东绿叶天然药物研究开发有限公司 人参皂苷c-k在制备治疗或预防肝纤维化的药物中的应用
WO2005102326A2 (en) * 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
LT1850873T (lt) * 2005-02-08 2019-04-10 Genzyme Corporation Antikūnas prieš tgf beta
KR20060114774A (ko) * 2005-05-02 2006-11-08 에스케이케미칼주식회사 (20Ｓ)-진세노사이드 Ｒｇ3을 함유하는 주름 예방 및개선용 화장료
US7932057B2 (en) * 2007-07-09 2011-04-26 Sheau-Long Lee Method for preparing 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (ginsenoside M1) by using sanqi leaves and stems
TW200930388A (en) * 2008-01-10 2009-07-16 Shih-Ming Chen Pharmaceutical composition for treating cisplatin induced nephropathy
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CN102942610A (zh) * 2012-11-26 2013-02-27 吉林农业大学 人参皂苷m1正丁酸酯的制备及其抗糖尿病医药用途
US9844560B2 (en) * 2014-05-02 2017-12-19 Sheau-Long Lee Use of ginsenoside M1 for treating lupus nephritis
US10172876B2 (en) * 2014-11-03 2019-01-08 Sheau-Long Lee Use of ginsenoside M1 for treating IgA nephropathy

Also Published As

Publication number Publication date
EP3146062A1 (en) 2017-03-29
JP2017515904A (ja) 2017-06-15
EP3146062A4 (en) 2017-11-29
EP3146062B1 (en) 2019-05-08
WO2015172746A1 (en) 2015-11-19
JP6626094B2 (ja) 2019-12-25
US20170087170A1 (en) 2017-03-30
TW201609111A (zh) 2016-03-16
TWI670063B (zh) 2019-09-01
KR102360315B1 (ko) 2022-02-08
KR20170007426A (ko) 2017-01-18
CN106795546A (zh) 2017-05-31
ES2739203T3 (es) 2020-01-29
US10357507B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3202086T3 (da) Tilstandsreplikation af virtuelle netværksfunktionsinstanser
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3757214T3 (da) Sammensætninger til modulering af sod-1-ekspression
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK2894272T3 (da) Beton med høj ydeevne
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3418273T3 (da) Derivater af flavagliner
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
DK3120153T3 (da) Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid
DK3146062T3 (da) Anvendelse af ginsenosid m1 til inhibering af nyrefibrose
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD